Search results
Results from the WOW.Com Content Network
Currently, the U.S. Food and Drug Administration has not approved any oral immunotherapy agents for asthma. [21] In January 2020, the FDA approved Palforzia for mitigating "allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts." [22] [23] It is the first drug approved for peanut allergies. It will not ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
In 1992, ALK and Abello merged. In the 1990s, ALK was the first company to launch sublingual immunotherapy drops (allergy immunotherapy administered as droplets under the tongue). In recent years, ALK's research and development strategy has been focused on introducing a range of sublingual immunotherapy tablets (SLIT-tablets).
Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYS ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
The sublingual route may also be used for vaccines against various infectious diseases. Thus, preclinical studies have found that sublingual vaccines can be highly immunogenic and may protect against influenza virus [4] [5] and Helicobacter pylori, [6] but sublingual administration may also be used for vaccines against other infectious diseases.
(Reuters) -The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in combination with chemoradiotherapy to treat newly ...
Talquetamab was approved for medical use in both the United States [9] [13] [14] and the European Union [15] in August 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication .